Letter: Incidence and Predictors of Major Gastrointestinal Bleeding in Patients on Aspirin, Low‐Dose Rivaroxaban or the Combination: Secondary Analysis of the COMPASS Randomised Controlled Trial

Dettagli Bibliografici
Autori principali:	Yu Yang, Yaling Li, Jun Li
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	Alimentary Pharmacology & Therapeutics
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Letter: Incidence and Predictors of Major Gastrointestinal Bleeding in Patients on Aspirin, Low‐Dose Rivaroxaban or the Combination: Secondary Analysis of the COMPASS Randomised Controlled Trial. Authors' Reply
di: Nauzer Forbes, et al.
Pubblicazione: (2024)

Letter: The Risk and Outcomes of Gastrointestinal Bleeding in Patients Using Warfarin or Direct Oral Anticoagulants
di: Jiaqi Shen, et al.
Pubblicazione: (2026)

Letter on ‘Clinical Trial: Effect of a 28‐Day Low FODMAP Diet on Gastrointestinal Symptoms Associated With Endometriosis ( EndoFOD )—A Randomised, Controlled Crossover Feeding Study’
di: Wancheng Zhao, et al.
Pubblicazione: (2025)

Letter: Reflections on the significance of myokines in alcohol‐associated liver disease
di: Yaomin Wang, et al.
Pubblicazione: (2024)

Letter: Interpreting Apparent P‐ CAB Superiority for Antithrombotic‐Associated Upper Gastrointestinal Bleeding
di: Xiaoqing Yang, et al.
Pubblicazione: (2026)

Meta‐Analysis of Placebo‐Treated Patients: Dropout Rates From Treatment in MASH Randomised Controlled Trials
di: Matheus Souza, et al.
Pubblicazione: (2025)

Editorial: Incidence and predictors of major gastrointestinal bleeding in patients on aspirin, low‐dose rivaroxaban or the combination: Secondary analysis of the COMPASS randomised controlled trial
di: Kanika Sehgal, et al.
Pubblicazione: (2024)

Research Communication: The Risk and Outcomes of Gastrointestinal Bleeding in Patients Using Warfarin or Direct Oral Anticoagulants
di: Lauren Holtslander, et al.
Pubblicazione: (2025)

Antiplatelet Resumption Timing in Post‐Percutaneous Coronary Intervention Gastrointestinal Bleeding
di: Darrick K. Li, et al.
Pubblicazione: (2026)

P‐ CAB vs. PPI for Upper Gastrointestinal Bleeding Prevention in Patients With Atherothrombotic Disease on Antithrombotic Therapy: A CDM Cohort Study
di: Min Joo Yoon, et al.
Pubblicazione: (2026)

Lubiprostone Reduces Fat Content on MRI‐PDFF in Patients With MASLD: A 48‐Week Randomised Controlled Trial
di: Mohamed El‐Kassas, et al.
Pubblicazione: (2025)

Clinical Trial: Semaglutide Versus Placebo in NIT ‐Assessed MASH —A Multicenter Randomised Placebo‐Controlled Trial ( SAMARA )
di: Veeral Ajmera, et al.
Pubblicazione: (2026)

Letter: Post‐Banding Ulcer Bleeding Is More Common With Urgent EBL and Renal Dysfunction
di: Jurij Maurer, et al.
Pubblicazione: (2026)

Letter: Lubiprostone—A Novel Therapeutic Avenue for Gastrointestinal Complications in MASLD
di: Hassan Javed, et al.
Pubblicazione: (2025)

Letter: Double‐Dose Hepatitis B Vaccination in IBD —A Step Forward in Protecting Immunosuppressed Patients
di: Luisa Bertin, et al.
Pubblicazione: (2026)

Letter: Predictors of Corticosteroid Response in Alcohol‐Related Hepatitis
di: Ewan Forrest, et al.
Pubblicazione: (2025)

Clinical Trial: Long Versus Short Tapering of Steroids in Steroid Responsive Moderate to Severely Active Ulcerative Colitis—A Randomised Controlled Trial
di: Ankit Kumar, et al.
Pubblicazione: (2026)

Letter: Tenofovir Alafenamide—The “Star of Potential” for Long‐Term Chronic Hepatitis B Treatment. A Deep‐Dive Analysis of Phase 3 Clinical Trials
di: YaoYao Dai, et al.
Pubblicazione: (2025)

Letter: Predictors of Corticosteroid Response in Alcohol‐Related Hepatitis—Authors' Reply
di: Francisco Idalsoaga, et al.
Pubblicazione: (2025)

Letter on ‘Post‐TIPS Overt Hepatic Encephalopathy Increases Long‐Term but Not Short‐Term Mortality in Cirrhotic Patients With Variceal Bleeding: A Large‐Scale, Multicentre Real‐World’
di: Silvia Nardelli, et al.
Pubblicazione: (2025)

Research Communication: Teriflunomide Does Not Affect Gluten‐Specific T‐Cell Activity in Coeliac Disease—A Randomised, Placebo‐Controlled Trial
di: Louise F. Risnes, et al.
Pubblicazione: (2025)

Risk of Variceal Bleeding in Patients Receiving Atezolizumab–Bevacizumab Treatment for Hepatocellular Carcinoma
di: Kanghee Park, et al.
Pubblicazione: (2025)

Letter: Liver Transplantation Outcomes for Alcohol‐Associated Liver Disease—Commentary on an Individual Patient Data Meta‐Analysis and Future Research Directions
di: Xinglin Li, et al.
Pubblicazione: (2026)

Clinical Trial: Immunogenicity of Double‐Dose Versus Standard‐Dose of Hepatitis B Virus Vaccine in Inflammatory Bowel Disease
di: Anupam Kumar Singh, et al.
Pubblicazione: (2025)

Clinical Trial: Effect of Abdominal Vibration Combined With Walking Exercise Programme on Bowel Preparation in Older Patients With Constipation
di: Yuan‐Yuan Zhang, et al.
Pubblicazione: (2025)

Research Communication: Effects of Screening Colonoscopy on Colorectal Cancer Mortality: Lessons From Comparative Analyses of Randomised Trials
di: Hermann Brenner, et al.
Pubblicazione: (2025)

Letter: Liver Transplantation Outcomes for Alcohol‐Associated Liver Disease—Commentary on an Individual Patient Data Meta‐Analysis and Future Research Directions. Authors' Reply
di: Ryan Yanzhe Lim, et al.
Pubblicazione: (2026)

Letter: Increased Prevalence of Visceral Obesity in Nonresponder Patients With Primary Biliary Cholangitis Based on Computed Tomography
di: Bo Li, et al.
Pubblicazione: (2024)

Letter: Clinical Trial Design Considerations for Hospitalised Patients With Ulcerative Colitis Flares and Application to Study Hyperbaric Oxygen Therapy in the NIDDK HBOT ‐ UC Consortium
di: Brian C. Weiner
Pubblicazione: (2025)

Letter: Bowel Preparation Quality in Patients With Crohn's Disease
di: Tamar Schildkraut, et al.
Pubblicazione: (2024)

Efficacy and Safety of Vedolizumab and Tofacitinib ( VETO ) Combination Therapy in Refractory Ulcerative Colitis Unresponsive to Anti‐ TNF and a Second‐Line Advanced Therapy: A Prospective Cohort Nested Within a Randomised Trial
di: Pardhu Bharath Neelam, et al.
Pubblicazione: (2025)

Letter: Dose and Donor Matter—Determining the Optimal Strategy for Faecal Microbiota Transplantation in Clostridioides difficile Infection. Authors' Reply
di: Sara Ellegaard Paaske, et al.
Pubblicazione: (2026)

Letter: Optimising Hepatitis B Vaccination in Inflammatory Bowel Disease – Expanding Strategies Beyond Double‐Dose Recombinant Vaccination
di: Yash Hegde, et al.
Pubblicazione: (2026)

Letter: Methodological Considerations in Interpreting Polygenic Risk Scores for Hepatocellular Carcinoma After SVR
di: Zhejin Shi, et al.
Pubblicazione: (2026)

Letter: Combination Therapies With Vitamin E for Metabolic Dysfunction‐Associated Steatotic Liver Disease
di: Stergios A. Polyzos, et al.
Pubblicazione: (2024)

Letter: Positivity of High‐Sensitivity HBsAg Test Was Significantly Associated With Poor Prognosis in Patients With Non‐HBV‐Related HCC
di: Xiaosong Li, et al.
Pubblicazione: (2024)

Letter: Does Serum HBV RNA Add Incremental Value for Hepatocellular Carcinoma Risk Stratification Beyond Established Predictors?
di: Yuanyan Sun, et al.
Pubblicazione: (2026)

Editorial: Variceal Bleeding in Patients Receiving Atezolizumab–Bevacizumab for Hepatocellular Carcinoma—Don't Ignore the Risk Factors! Authors' Reply
di: Jonggi Choi
Pubblicazione: (2025)

Effects of Resmetirom on Metabolic‐Dysfunction Associated Steatohepatitis in Patients With Weight Loss and/or Diabetes Taking Glucagon‐Like Peptide‐1 Receptor Agonists and Other Diabetes Therapies: A Secondary Analysis of the MAESTRO ‐ NASH Trial
di: Mazen Noureddin, et al.
Pubblicazione: (2025)

Post‐TIPS Overt Hepatic Encephalopathy Increases Long‐Term but Not Short‐Term Mortality in Cirrhotic Patients With Variceal Bleeding: A Large‐Scale, Multicenter Real‐World Study
di: Yi Xiang, et al.
Pubblicazione: (2025)

Documenti analoghi

Documenti analoghi